Talon recruits first patient in study of new vincristine formulation

Submitted by Ross Bonander Thu 12/01/2011

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Talon Therapeutics has enrolled the first patient in a Phase III study of the company's product candidate Marqibo in patients aged 60 or older with newly diagnosed non-Hodgkin's lymphomas.

The study, referred to as OPTIMAL>60, is being conducted by one of the most prestigious study groups in the world, the German High-Grade NHL Study Group.

Marqibo is a formulation of the well-known chemotherapy drug vincristine, namely it is vincristine sulfate liposomes injection.

The study, into which Talon hopes to recruit 1,000 patients, will examine the efficacy of the R-CHOP regimen (given every 14 days) against R-CHMP (also given evert 14 days). In short, standard vincristine will be replaced in the second group with Marqibo.

According to Steven R. Deitcher M.D., President, Chief Executive Officer and Board Member of Talon Therapeutics, "We believe Marqibo has the potential to benefit patients with NHL... by providing vincristine dose intensification while maintaining a predictable and manageable safety profile."

Source: MarketWatch

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.